PEGylation of therapeutic proteins is commonly used to
extend half-lives
and to reduce immunogenicity. However, reports of antibodies toward
PEGylated proteins and of poly(ethylene glycol) (PEG) accumulation
suggest that efficacy and safety concerns may arise. To understand
the relationship among the pharmacology, immunogenicity, and toxicology
of PEGylated proteins, we require knowledge of the disposition and
metabolic fate of both the drug and the polymer moieties. The analysis
of PEG by standard spectrophotometric or mass spectrometric techniques
is problematic. Consequently, we have examined and compared two independent
analytical approaches, based on gel electrophoresis and nuclear magnetic
resonance (NMR) spectroscopy, to determine the biological fate of
a model PEGylated protein, 40KPEG-insulin, within a rat
model. Both immunoblotting with an antibody to PEG and NMR analyses
(LOD 0.5 μg/mL for both assays) indicated that the PEG moiety
remained detectable for several weeks in both serum and urine following
intravenous administration of 40KPEG-insulin (4 mg/kg).
In contrast, Western blotting with anti-insulin IgG indicated that
the terminal half-life of the insulin moiety was far shorter than
that of the PEG, providing clear evidence of conjugate cleavage. The
application of combined analytical techniques in this way thus allows
simultaneous independent monitoring of both protein and polymer elements
of a PEGylated molecule. These methodologies also provide direct evidence
for cleavage and definition of the chemical species present in biological
fluids which may have toxicological consequences due to unconjugated
PEG accumulation or immunogenic recognition of the uncoupled protein.